White coat adherence effect on glucose control in adult individuals with diabetes. by Züger, Thomas et al.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 9 2
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
2
1
8
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Contents available at ScienceDirectDiabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabresWhite coat adherence effect on glucose control in
adult individuals with diabeteshttps://doi.org/10.1016/j.diabres.2020.108392
0168-8227/ 2020 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author at: Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern
Hospital, University of Bern, Freiburgstrasse 15, 3010, Bern, Switzerland.
E-mail address: thomas.zueger@insel.ch (T. Zueger).Thomas Zueger a,b,*, Manuel Gloor a, Vera Lehmann a, Andreas Melmer a, Mathias Kraus b,
Stefan Feuerriegel b, Markus Laimer a, Christoph Stettler a
aDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland
bDepartment of Management, Technology, and Economics, ETH Zurich, 8006 Zurich, SwitzerlandA R T I C L E I N F O A B S T R A C TArticle history:
Received 28 March 2020
Received in revised form
6 August 2020
Accepted 21 August 2020
Available online 25 August 2020
Keywords:
White coat adherence
Diabetes
Glycemic control
continuous glucose monitoring (rt/
isc CGM)Background: White coat adherence (WCA) is defined as an increased adherence to treat-
ment regimens directly before a visit with a healthcare provider. Little is known on the
effect of WCA on glucose control in adult patients with diabetes mellitus.
Methods: The present study is based on 618 CGM-observations of 276 patients with diabetes
treated between January 2013 and July 2018. The analysis compares data from the 3 days
prior to a visit (p1) with the preceding 25 days (p2).
Results: Sensor use was higher during p1 than p2 (92.8 ± 7.3% vs 88.8 ± 7.5%; p < 0.001).
Mean glucose [MG] and coefficient of variation [CV] were lower in p1 compared to p2 (MG
163.9 ± 39.2 mg/dL vs 166.9 ± 35.7 mg/dL, p = 0.001; CV 33.5 ± 8.4% vs 36.0 ± 7.0%,
p < 0.001; respectively). Time in range (70–180 mg/dL) was higher in p1 than p2 (61.4 ± 21.
2% vs 60.0 ± 18.4%, p = 0.002). Sensitivity-analysis showed that WCA effect was mainly
detected in patients with HbA1c > 7% [53 mmol/mol].
Conclusion: This study reveals a WCA effect on pre-visit glucose control in adult patients
with diabetes. The effect was most pronounced in patients with moderate to poor glycemic
control. In these patients, analysis of CGM data should encompass a minimum of 1 to
2 weeks prior to a consultation.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Impaired adherence to medication and treatment regimens is
a relevant issue and may affect up to 50% of patients with
chronic conditions such as diabetes [1]. From drug studies it
is known that compliance with prescription is significantlyhigher immediately before and after clinical visits compared
to the time period in between the visits [2–5]. The increased
adherence to treatment regimens in the days prior to the visit
with a healthcare provider (HCP) is generally referred to as
white coat adherence (WCA) and may lead to misinterpreta-
tion of general glycemic control if the time period is not cho-University
Table 1 – Patient characteristics.
Characteristics Overall population (n = 276)
Observations 618
Observations per patient 2.24 ± 1.56
Age [years] 47.0 ± 16.7
Gender [n (%)]
Female 99 (35.9%)
Male 177 (64.1%)
HbA1c [% (mmol/mol)] 7.4 ± 1.1 (57 ± 12)
Diabetes duration [years] 18.2 ± 12.3
Type of diabetes [n (%)]
Type 1 189 (68.5%)
Type 2
Pancreatogenic
GDM
MODY
unknown
62 (22.5%)
14 (5.1%)
1 (0.3%)
2 (0.7%)
8 (2.9%)
Treatment modality [n (%)]
MDI 129 (46.8%)
CSII
Non-insulin
Insulin + non-insulin
unknown
98 (35.5%)
2 (0.7%)
44 (15.9%)
3 (1.1%)
CGM device [n (%)]
Medtronic enlite 60 (21.7%)
Dexcom
Free Style libre
64 (23.2%)
152 (55.1%)
Patient characteristics of individuals included in the main analysis
(p1 vs p2). GDM, gestational diabetes; MODY, maturity-onset dia-
betes of the young; MDI, multiple daily injections; CSII, continuous
subcutaneous insulin infusion; non-insulin encompasses oral
antidiabetic drugs and/or GLP-1 receptor agonists.
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decision-making and can even result in erroneous or missing
treatment adaptations [6].
WCA has been reported in children and adolescents with
diabetes, increasing the frequency of blood glucose measure-
ments, insulin boluses and carbohydrate documentation
before a HCP visit [7,8]. However, there is currently no study
formally assessing a potential WCA effect on glycemic control
in adult patients with diabetes. The increasing availability of
continuous and intermittent scanning glucose monitoring
(rtCGM & iscCGM) devices provides an optimal framework
for a detailed analysis of a potential WCA effect on glycemia.
The present study aimed at assessing a potential WCA
effect on glucose control in adult patients with diabetes based
on rt/iscCGM readings prior to a clinical visit. The hypothesis
was that glucose control is significantly better in the days
directly before a visit as compared to the previous period.
2. Methods
This was an observational, retrospective single-center study
approved by the local ethics committee. A general informed
consent for the analysis of health-related data was obtained
for all participants. We screened all patients with diabetes
treated at our tertiary diabetic referral center between Jan-
uary 2013 and July 2018 who were using a rt/iscCGM system.
A study of pediatric patients with epilepsy demonstrated an
increase in adherence during the 3 days preceding a clinical
visit [6]. Based thereon, we assessed WCA by comparing
sensor-related glucose data of day 0 to day 3 prior to the visit
(p1) with the period between day 4 to day 28 before the
visit (p2). As a secondary analysis to assess for an extended
WCA effect, we compared a longer pre-visit period (day 0 to
day 7, p1ext) with the period between day 8 and day 28
(p2ext). Since current consensus guidelines recommend a
sampling period of at least 2 weeks we further compared
the 14 days prior to the visit (p1equal) with the preceding
14 days (p2equal) [9]. To corroborate the validity of shorter-
term CGM-data we analysed the correlation between the full
28 days and sampling periods of 3, 7, 14 and 21 days prior to
the clinical visit. Furthermore, we compared correlation of
p1/p2, p1ext/p2ext and p1equal/p2equal with the full 28 days.
According to current guidelines, patients were only
included in the analysis if rt/iscCGM-data were available for
at least 70% of the two corresponding time periods [9]. Addi-
tional inclusion criteria were a diagnosis of diabetes mellitus
according to ADA guidelines [10], age > 16 years, and written
informed consent for the retrospective analysis of CGM data.
CGM records were exported from the proprietary manufac-
turers’ software and then processed using the Glyculator 2.0
web application, which is a validated tool for analyzing CGM
records [11]. Patient characteristics including diabetes dura-
tion, treatment modality and HbA1c values were obtained
from electronic medical records. Diabetes duration was calcu-
lated based on the time-point of diagnosis denoted in the
medical record. All statistical analyzes were performed using
STATA version 16.0 (StataCorp LLC, College Station, Texas,
USA). Unless otherwise specified, results are reported as
mean ± standard deviation (SD). Time periods were comparedusing paired t-tests andmixed linear models with patient as a
random effect. Analysis of potentially modifying factors was
performed using ANOVA and multivariable mixed model
analysis including age, sex, type and duration of diabetes,
and type of treatment.
Correlation of the individual CGM parameters over the dif-
ferent sampling periods was assessed using correlation coef-
ficients with listwise deletion of missing values. An alpha
level of 5% was defined as statistically significant.
3. Results
Out of 433 screened patients, 276 fulfilled the inclusion crite-
ria for the main analysis (64.1% male, 35.9% female; mean
HbA1c 7.4 ± 1.1% [57 ± 12 mmol/mol], mean age 47.0 ± 16.7yr
s, mean diabetes duration 17.3 ± 12.2yrs; additional patient
characteristics are summarized in Table 1). This resulted in
a total of 618 observations, both 3 and 25 days prior to the
visit. For the secondary analysis of extended periods p1ext
and p2ext, 274 patients met the inclusion criteria, resulting
in 616 observations. For periods p1equal and p2equal, 263
patients fulfilled the inclusion criteria, resulting in 587
observations.
The results of the analysis comparing p1 to p2, and p1ext
compared to p2ext are given in Table 2. Sensor use was higher
during p1 compared to p2 (92.5 ± 7.3% vs 88.8 ± 7.5%; p < 0.001)
Table 2 – rt/isc CGM parameters prior to clinical visits.
p1
(day 0 to 3)
p2
(day 4 to 28)
p-value p1ext
(day 0 to 7)
p2ext
(day 8 to 28)
p-value
Sensor in use (%) 92.5 ± 7.3 88.8 ± 7.5 <0.001 91.1 ± 6.9 88.9 ± 7.6 <0.001
HbA1c  7% 92.8 ± 6.8 89.4 ± 7.2 <0.001 91.7 ± 6.3 89.7 ± 7.3 <0.001
HbA1c > 7% 92.3 ± 7.5 88.5 ± 7.7 <0.001 90.7 ± 7.3 88.5 ± 7.7 <0.001
Mean glucose (mg/dl) 163.9 ± 39.2 166.9 ± 35.7 0.001 165.3 ± 37.4 166.9 ± 35.4 0.042
HbA1c  7% 142.4 ± 26.0 142.7 ± 20.8 0.67 142.8 ± 24.0 142.7 ± 21.2 0.87
HbA1c > 7% 178.5 ± 40.2 183.0 ± 34.9 0.002 180.2 ± 37.7 182.6 ± 34.3 0.044
Time in range (70–180 mg/dl) 61.4 ± 21.2 60.0 ± 18.4 0.005 61.1 ± 19.7 60.0 ± 18.5 0.011
HbA1c  7% 73.4 ± 15.8 73.0 ± 11.8 0.48 73.1 ± 13.6 73.0 ± 12.3 0.85
HbA1c > 7% 53.5 ± 20.8 51.4 ± 17.1 0.010 53.2 ± 19.4 51.7 ± 17.1 0.018
Time > 180 mg/dl 34.3 ± 22.2 35.9 ± 19.7 0.002 34.8 ± 20.9 36.0 ± 19.6 0.012
HbA1c  7% 21.3 ± 15.8 21.7 ± 12.2 0.58 21.6 ± 14.0 21.6 ± 12.5 0.98
HbA1c > 7% 42.8 ± 21.8 45.3 ± 18.1 0.003 43.5 ± 20.3 45.2 ± 17.9 0.015
Time > 250 mg/dl 11.3 ± 14.9 12.5 ± 13.7 <0.001 11.9 ± 14.3 12.4 ± 13.6 0.068
HbA1c  7% 4.7 ± 7.7 4.6 ± 5.4 0.83 4.8 ± 6.8 4.7 ± 5.7 0.75
HbA1c > 7% 15.9 ± 16.9 17.7 ± 15.1 0.002 16.6 ± 16.1 17.4 ± 15.0 0.11
Time < 70 mg/dl 4.3 ± 6.8 4.1 ± 4.7 0.40 4.1 ± 5.3 4.0 ± 4.6 0.77
HbA1c  7% 5.2 ± 6.7 5.3 ± 5.5 0.74 5.3 ± 5.8 5.4 ± 5.6 0.71
HbA1c > 7% 3.7 ± 6.8 3.3 ± 4.0 0.16 3.3 ± 4.8 3.1 ± 3.6 0.50
Time < 54 mg/dl 1.4 ± 4.1 1.3 ± 2.3 0.42 1.3 ± 3.0 1.3 ± 2.2 0.92
HbA1c  7% 1.6 ± 4.1 1.6 ± 2.6 0.99 1.6 ± 3.0 1.7 ± 2.8 0.49
HbA1c > 7% 1.3 ± 4.1 1.1 ± 2.0 0.28 1.1 ± 2.9 1.0 ± 1.8 0.67
CV (%) 33.5 ± 8.4 36.0 ± 7.0 <0.001 34.7 ± 7.6 35.8 ± 7.1 <0.001
HbA1c  7% 33.1 ± 8.0 35.2 ± 6.6 <0.001 34.4 ± 7.1 35.2 ± 7.0 0.021
HbA1c > 7% 33.9 ± 8.7 36.4 ± 7.4 <0.001 35.0 ± 8.1 36.2 ± 7.3 <0.001
MAGE (mg/dl) 135.4 ± 40.5 143.8 ± 33.2 <0.001 146.3 ± 43.7 150.9 ± 40.9 <0.001
HbA1c  7% 121.7 ± 34.7 127.4 ± 26.1 0.012 127.3 ± 36.7 128.1 ± 32.0 0.65
HbA1c > 7% 149.9 ± 41.4 159.7 ± 32.1 <0.001 159.3 ± 44.1 164.7 ± 39.8 0.001
MODD (mg/dl) 58.2 ± 21.7 59.4 ± 15.4 0.18 63.5 ± 22.4 63.6 ± 19.0 0.87
HbA1c  7% 50.7 ± 16.3 52.0 ± 12.4 0.27 54.2 ± 17.5 53.6 ± 15.3 0.47
HbA1c > 7% 66.6 ± 24.1 66.7 ± 14.5 0.91 70.2 ± 23.4 70.1 ± 18.5 0.93
HbA1c 7% = 53 mmol/mol. For comparison p1 vs. p2 n = 618 (HbA1c  7% n = 235, HbA1c > 7% n = 350, HbA1c not available n = 33); For comparison
p1ext vs. p2ext n = 616 (HbA1c  7% n = 231, HbA1c > 7% n = 350, HbA1c not available n = 35). Significant p-values are printed in bold.
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88.9 ± 7.6%; p < 0.001). For p1 compared to p2 mean glucose
(163.9 ± 39.2 mg/dL vs. 166.9 ± 35.7 mg/dL; p = 0.001), CV
(33.5 ± 8.4% vs. 36.0 ± 7.0%; p < 0.001) and mean amplitude
of glycemic excursion [MAGE] (135.4 ± 40.5 mg/dL vs. 143.8 ±
33.2 mg/dL; p < 0.001) were significantly lower. Time in target
range (TIR 70–180 mg/dL) was higher in p1 than p2 (61.4 ± 21.
2% vs 60.0 ± 18.4%, p = 0.005), whereas time above 180 mg/dL
was lower in p1 compared to p2 (34.3 ± 22.2% vs 35.9 ± 19.7%,
p = 0.002) and this was also observed for time above 250 mg/
dL (11.3 ± 14.9% vs 12.5 ± 13.7%; p < 0.001). There was no dif-
ference for time below 70 mg/dL (4.3 ± 6.8% vs. 4.1 ± 4.7%,
p = 0.4).
For the comparison of p1ext and p2ext differences tended to
be smaller but were still present for sensor use, mean glucose,
TIR, time > 180 mg/dL and parameters of glucose variability
(Table 2). When comparing p1equal and p2equal only marginal
differences were detectable for TIR, time > 180 mg/dL and
MAGE (see supplementary data).
When stratifying analysis according to HbA1c, differences
were more pronounced in patients with moderate to poor
control (HbA1c > 7% [53 mmol/mol]) for all the glycemic
parameters except time in low glucose range and mean of
daily differences. In well-controlled patients (HbA1c  7%
[53 mmol/mol]) only sensor use, CV and MAGE were lowerin p1 compared to p2 (Table 2). However, there were no signif-
icant differences (p > 0.05 for all comparisons) according to
diabetes treatment (CSII, MDI, other), type of diabetes (DM1,
DM2, other), gender, age (grouping by decade), or diabetes
duration (<10y, 10-20y, >20y).
To account for the multiple observations in several indi-
viduals, we performed a sensitivity analysis using a mixed
linear model with patient as a random effect. The results
remained similar, corroborating the robustness of our find-
ings (p < 0.001 for sensor use, p = 0.002 for mean glucose,
p = 0.008 for TIR, p = 0.004 for time > 180 mg/dl, p = 0.001
for time > 250 mg/dl, p = 0.40 for time < 70 mg/dl, p = 0.42
for time < 54 mg/dl and p < 0.001 for CV, respectively). How-
ever, WCA effect differed according to glycemic control
(HbA1c  7% vs. > 7%, Table 2), particularly for mean glucose
(p = 0.034) and for time > 250 mg/dl (p = 0.017). This finding
was robust even if models were adjusted for age, sex, type
and duration of diabetes, and treatment type (p = 0.034 and
0.019, respectively).
To assess overall validity of our dataset and as suggested
by previous investigators [12] we assessed the correlation of
each parameter during the individual sampling periods (i.e.
3, 7, 14, and 21 consecutive days prior to the visit) with the full
28 days (see Fig. 1). Overall, there was an increasing correla-
tion for all CGM parameters when extending the sampling
Fig. 1 – Correlation coefficient (R) between the full 28 days and increasing number of sampling days prior to a clinical visit for
differing real-time and intermittent scanning continuous glucose monitoring (rt/isc CGM) metrics in the overall population
(panel A), in individuals with HbA1c  7% [53 mmol/mol] (panel B) and individuals with HbA1c > 7% [53 mmol/mol] (panel C).
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[53 mmol/mol]) showed a higher correlation between days 3,
7 14, 21 and the full 28 days for all CGM-parameters, except
for time < 54 mg/dl (see Fig. 1B) compared to moderately/
poorly controlled patients (see Fig. 1C). This discrepancy
was especially pronounced for shorter time-periods before a
visit (i.e. 3 and 7 days) and decreased with longer time-
periods.
4. Discussion
The main findings of the present analysis assessing white
coat adherence (WAC) based on rtCGM and iscCGM data in
adult patients with diabetes are fourfold: First, we found a sig-
nificantly improved glucose control in the days directly prior
to a clinical visit; Second, the effect was consistent across
all parameters under investigation; Third, the effect was more
pronounced in patients with moderate to poor glycemic con-
trol (i.e. HbA1c values  7% [53 mmol/mol]); And fourth, the
effect diminished over the first week prior to a visit and was
absent when the period was extended to 2 weeks.
To the best of our knowledge, the present study thereby is
the first to assess a WCA effect on glucose control in adult
patients with diabetes. The fact that differences between a
three-day period compared with the previous 25 days were
consistently observed and revealed statistical significance
points towards an adequately powered sample size and cor-
roborates the concept of a true WCA effect on glucose control
in adult individuals with diabetes. In the present study, the
effect was mainly reflected by a higher time in target range
and a higher percentage of sensor use, as well as lower mean
glucose, time above target, and coefficient of variation.
Our findings of a WCA effect are in line with two recent
reports in children and adolescents with diabetes showing
more frequent blood glucose measurements, carbohydrate
inputs, and delivered insulin boluses prior to a clinical visit
[7,8]. However, both studies did not include CGM data and
therefore, no conclusion could be drawn regarding diabetes
control in the days prior to the visits in this pediatric popu-
lations. Of interest, in the present analysis besides parame-
ters of glycemic variability no relevant WCA effect was
observed in well-controlled patients (i.e. HbA1c  7%
[53 mmol/mol]), although these patients also showed a sig-
nificantly higher sensor utilization prior to the visit. This lat-ter finding may be related to the fact that patients with
better control generally have a higher adherence, thereby
minimizing the need and the potential to further optimize
therapy before visits.
In our analysis, WCA effect was most strongly observed
when the analysis was focused on the 3 days prior to a visit.
This is fully in line with pharmacological studies in other
areas of medicine (e.g. HIV, neurology, etc) typically demon-
strating a WCA effect across the 2–3 days preceding contact
with healthcare providers [3,6]. When extending the period
of assessment, the effect in the present analysis diminished
over the first week and was absent when comparing the first
2 weeks to the 2 weeks before. In a clinical setting this indi-
cates that when analyzing CGM data, particularly in patients
with moderate to poor overall control, the influence of a
potential WCA effect can be minimized by extending the
analysis period to 2 weeks prior to a visit. Of note, 2 weeks
is a generally accepted time period for the interpretation of
CGM results since previous studies have shown good correla-
tion with longer term glycemic control. For instance, a recent
study by Riddlesworth et al. demonstrated that correlation
between long-term glycemic control and CGM-metrics
improved with increasing number of days of data collection,
plateauing at sampling duration of around 14 days [12]. This
is well in line with our findings, showing a robust and similar
increase of correlation coefficients over time. Of interest, the
lower correlation of CGM parameters between the first 3 days
and the full 28 days prior to a visit in moderately/poorly con-
trolled patients further corroborates the hypothesis of a more
pronounced WCA effect in this population. Noteworthy, for
time below target range we found generally a more modest
correlation between shorter pre-visit periods (i.e. 3 and 7 days)
and the full 28 days. Based on this longer time periods should
be considered to allow for a robust assessment of hypo-
glycemia risk when analyzing CGM read-outs both in moder-
ately/poorly controlled patients, but also in well- controlled
individuals.
While the present study is based on a careful analysis of
data, we have to acknowledge several limitations. First, this
was a retrospective study. Therefore, we cannot entirely rule
out selection bias and systematic errors. We tried to minimize
this by including every patient treated with a rt/iscCGM at our
department. Still, this was a single center study at a tertiary
referral center with Caucasian predominance, thereby limit-
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 9 2 5ing generalization to other populations. On the other hand,
the sample size was substantial and covered a wide range
of patients with diabetes, and effects were consistently
observed across all subgroups. Third, we had no access to
CGM-data of the time-period after the clinical visits, preclud-
ing statements regarding a sustained WCA effect after visits.
This aspects needs to be covered in future prospective stud-
ies. Fourth, while absolute difference in some parameters
was relatively small, particularly in well-controlled patients,
the effect was more pronounced in patients with moderate
to poor glycemic control, thereby pointing towards higher
clinical importance in this latter group. Fifth, time point of
diabetes diagnosis was based on information derived from
the medical record. Therefore, we cannot exclude that some
of the patients previously suffered from undiagnosed diabetes
leading to an underestimation of diabetes duration, particu-
larly for type 2 diabetes. However, since the present analysis
is focused on changes in diabetes control directly prior to a
consultation, this is unlikely to have interfered with the inter-
pretation of the results.
5. Conclusion
The present study is the first to report on a WCA effect on glu-
cose control by showing a significantly improved glucose con-
trol based on rt/iscCGM in the days directly prior to a clinical
visit in adult patients with diabetes. The effect was consis-
tent, and was most pronounced in patients with moderate
to poor glycemic control. Based on these findings, analysis
of CGM data, particularly in adult patients with non-optimal
diabetes control, should encompass a period of adequate
length (i.e. a minimum of 1–2 weeks) before consultation to
avoid misinterpretation due to WCA.
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